TrialPath

Find a study

Match me to a study

236 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidney

128 studies on the map

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Alliance For Multispecialty Research - Daphne, DaphneA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Advanced Cardiovascular, LLC, Alexander CityMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — University of Alabama Saint Vincent's Birmingham, BirminghamEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Pinnacle Research Group, LLC, AnnistonCombined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Nephrology of North Alabama, Decatur"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" — Scottsdale Research Institute, PhoenixMulticenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients — Harmonex Neuroscience Research, DothanA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder — IMA Clinical Research Phoenix, PhoenixA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — Seaport Investigator Site, ChinoA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder — UAB Psychiatry and Behavioral Neurology, BirminghamA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) — Harmonex Neuroscience Research, DothanA Study of Brenipatide in Adult Participants With Major Depressive Disorder — Accellacare - Moorpark, MoorparkStudy of ALTO-300 in MDD — Site 200, PhoenixStudy of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) — Autobahn Site #131, BirminghamALTO-207 in Adults With Treatment-resistant Depression (TRD) — Site 7074, BirminghamPramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Alabama CRS, BirminghamE-Mindfulness Approaches for Living After Breast Cancer — Mayo Clinic Hospital in Arizona, PhoenixA Study to Evaluate the Effectiveness of DT-101 in Patients With Depression — Draig Clinical Site, BentonvilleA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. — Pillar Clinical Research /ID# 226504, BentonvilleA Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) — Noble Clinical Research, TucsonLong-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleA Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, OceansideA Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms — Clinical Research Site, BellflowerPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — University of Alabama at Birmingham, BirminghamStudy of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — University of Alabama at Birmingham, HuntsvilleStudy to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder — University of Alabama - Huntsville Regional Medical Campus /ID# 267818, HuntsvilleStudy of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder — Clinical Site, BirminghamStudy of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder — Clinical Site, ChandlerEvaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder — Vanda Investigational Site, PhoenixZelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, ChinoA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder — Harmonex /ID# 277517, DothanA Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — NoesisPharma, LLC, PhoenixStudy to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder — Vanda Investigational Site, PhoenixA Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamA Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) — Noble Clinical Research, TucsonALTO-100 in Bipolar Disorder With Depression (BD-D) — Site 6036, ChandlerA Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) — Lighthouse Psychiatry, GilbertA Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) — IMA Clinical Research- Phoenix, PhoenixA Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor — Neurocrine Clinical Site, BryantRE104 Safety and Efficacy Study in Generalized Anxiety Disorder — Lighthouse Psychiatry, GilbertACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — University of Alabama at Birmingham, BirminghamSotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease — Stanford University Medical Center, StanfordStudy to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, Little RockA Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder — CI Trials, BellflowerA Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors — Site 108, ChandlerClinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol — Clinical Research Site, ChinoA Study of NTX-1472 in Social Anxiety Disorder — SOAR Clinical Study Site, PheonixNBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleA Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder — Vistagen Clinical Site, Sherman OaksPCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study — Mood Institute, MilfordCombination of Novel Therapies for CKD Comorbid Depression — Stony Brook University Medical Center, Stony BrookMechanisms of Semaglutide Therapy in Heart Failure Patients — Greenstone Biosciences, Palo AltoModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraENA-001 for Opioid Induced Respiratory Depression — South Florida Research Phase I-IV, MiamiA Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression — Draig Clinical Site, DeSotoGamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression — Wells Medicine, HoustonStudy of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders — National Institutes of Health Clinical Center, BethesdaInflammation and Depression in People With HIV — Grady Memorial Hospital, AtlantaFeasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department — University of Kansas Strawberry Hill Campus, Kansas CityKetamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients — Texas Tech University Health Sciences Center Lubbock, LubbockPramipexole to Enhance Social Connections — University of California, San Diego, San DiegoBuspirone and Melatonin for Depression Following Traumatic Brain Injury — Massachusetts General Hospital, BostonBiomarker-guided rTMS for Treatment Resistant Depression — Stanford University, StanfordSearch for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness — Acacia Clinics, SunnyvaleSubanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients — Mayo Clinic, JacksonvilleAβ Dynamics in LLMD — NYU Langone Health, New YorkACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression — Stanford Psychiatry and Behavioral Sciences Department, Palo AltoSleep, Dreaming, and Virtual Reality for Mental Health — Northwestern University, EvanstonMetabolic Effects of Angiotensin-(1-7) — Vanderbilt University Medical Center, NashvillePioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants — Texas Diabetes Institute/UH, San AntonioSympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study) — University of Kansas Medical Center, Kansas CityPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis — University of Alabama at Birmingham, BirminghamEffects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults — University of Texas Health Science Center at San Antonio, San AntonioPrevention of Progression of Prediabetes, Obesity and CV Risk — University of Texas Health Science Center at San Antonio, San AntonioImproving Coronary Vascular Health in Women — Massachusetts General Hospital, BostonAcute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes — University of Texas Health Science Center at San Antonio, San AntonioEffect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT — Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), TorranceErtugliflozin in Chronic Heart Failure — Yale School of Medicine, New HavenEffect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease — Northwestern University, ChicagoKetamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression — VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor: Vascular Function in Health and Disease — George E Wahlen VA Medical Center, Salt Lake CityKetamine Alcohol (in Treatment-Resistant Depression) — University of Iowa Health Care, Iowa CityInvestigation to Understand and Optimize Psilocybin — Vail Health Behavioral Health, EdwardsThe Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder — Athinoula A. Martinos Center for Biomedical Imaging, CharlestownLeveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City — Washington University School of Medicine, St LouisApimostinel + Automated Neurocognitive Training for Depression — Western Psychiatric Institute and Clinic, PittsburghImaging Depression in Parkinson's Disease — Yale University, New HavenSynaptic Mechanisms of Continuous Theta Burst Stimulation in Depression — McLean Hospital, BelmontAllopregnanolone (Zuranolone) in Post-stroke Depression — Duke South Neurology Clinic 1L, DurhamPsilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease — Johns Hopkins Center for Psychedelic and Consciousness Research, BaltimoreAcute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A) — University of Cincinnati, CincinnatiA Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression — UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los AngelesPharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation — Mclean Hospital, BelmontOvarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression — University of North Carolina, Chapel Hill, Chapel HillPattern Separation in Major Depressive Disorder — New York State Psychiatric Institute (NYSPI), New YorkPromoting Active Therapy: Path to Wellness — Kansas State University, ManhattanTraining Reward Responsiveness Through Virtual Reality — University of California, Los Angeles, Los AngelesEfficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder — McLean Hospital, BelmontDBS for Depression — Zucker Hillside Hospital, QueensProcesses and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression — Laureate Institute for Brain Research, TulsaDouble-blind, Placebo-controlled Study in Adults With Major Depressive Disorder — Collaborative Neuroscience Network, Garden GrovePsilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder — Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New YorkSlow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II — Washington University School of Medicine/Barnes-Jewish Hospital, St LouisIdentifying and Treating Depression in the Orthopaedic Trauma Population — Wake Forest University Health Sciences, Winston-SalemProbiotic Administration for Adolescent Depression — UCSF, San FranciscoNeuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder — National Institutes of Health Clinical Center, BethesdaLeucine in Midlife Depression — Emory University Hospital, AtlantaPersonalized Ultrasonic Brain Stimulation for Depression (R61) — University of Utah, Salt Lake CityNeuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV — Massachusetts General Hospital, BostonPsilocybin in Chronic Low Back Pain and Depression — Johns Hopkins University School of Medicine, BaltimoreEstablishing Multimodal Brain Biomarkers for Treatment Selection in Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, AustinEvaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression — Laureate Institute for Brain Research, TulsaJAK Signaling in Depression — Emory University, AtlantaModulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains — Lindner Center of Hope, MasonComputerized Cognitive Behavioral Therapies for Suicide Prevention and Depression — Eastern Colorado Health Care System, AuroraDopaminergic Therapy for Anhedonia - 2 — Emory University Hospital, AtlantaAcceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesBezafibrateTreatment for Bipolar Depression: A Proof of Concept Study — The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, BostonSerotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures — Wake Forest University Health Sciences, Winston-SalemClemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression — University of Illinois College of Medicine, ChicagoDetermining Optimal Treatment Sequences in Anxious Depression (DOTS-AD) — University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, CincinnatiKetamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression — Icahn School of Medicine at Mount Sinai, New York[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET — National Institutes of Health Clinical Center, BethesdaSleep to Reduce Incident Depression Effectively in Peripartum — Henry Ford Medical Center, NoviLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression — Massachusetts General Hospital, BostonStudy of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans — Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West HavenNebulized Ketamine for the Treatment of Major Depressive Disorder — Maimonides Medical Center, Brooklyn

Showing the 150 nearest — narrow your filters for fewer, closer studies.